U.S. listed Genesis Pharmaceuticals Enterprises,a pharmaceutical company with its principal operations in China, has announced that an American Arbitration Association arbitration panel rejected requests by Capital Research Group, Inc. to award it USD13.8 million and Capital Research Group Partners, Inc. to award it USD13.7 million in a joint arbitration proceeding against Genesis alleging the breach [...]

Genesis Pharmaceuticals Enterprises, Inc., a pharmaceutical company in the People's Republic of China, has announced that the company has received approval from the Chinese State Food and Drug Administration to start producing and distributing Radix Isatidis Dispersible Tablets.